Grant: Collaborative Health Research Projects
University of Calgary
$320,364.00
Development of a Blood Test for Colorectal Cancer based on Metabolomic Signature
FY 2019-20
Summary
Colorectal cancer (CRC) is the second leading cause of cancer death in the western world.Ideally, CRC will be detected early because treatments become progressively morecomplicated, toxic and expensive in later disease stages, and the survival is best in earlystage of disease. That is the basis of screening. Currently, the gold standard screening test iscolonoscopy, which is invasive, expensive and difficult to perform on large populations. Onestrategy is to enrich the subgroup that requires a colonoscopy by doing a stool test (called afecal immunohistochemical test, FIT). The problem is that compliance for stool tests is lessthan 40% because testing stool is objectionable and inconvenient. We have developed ablood test based on the chemical composition of serum. This test is quite sensitive and it hasalready been tested on over 600 patients. In this project, in collaboration with Med-LifeDiscoveries and Innovate Calgary, as well as a multidisciplinary science team, we will furtherrefine the test, then create a diagnostic test that can be used in a typical clinical laboratory.Software will be developed to enhance the capability to analyze test results. Finally, we willtest the new diagnostic test on blood samples collected from close to 3500 individuals whohad screening colonoscopies. At the end, we will have a convenient, clinically applicable testthat will be tested in the future in a larger clinical trial that would inform regulatory agenciesand clinicians on the value of this new test as an alternative screening tool.
Program
Collaborative Health Research Projects
Recipient
Location
Alberta, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data
As published
Application id
523397-2018
Name nom
Bathe, Oliver
Department département
Surgery
Organization id
11
Institution établissement
University of Calgary
Province en
Alberta
Province fr
Alberta
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2019
Competition year année de concours
2018
Award amount
320364
Program id
CHRPJ
Program name en
Collaborative Health Research Projects
Program name fr
Projets de recherche concertée sur la santé
Group en
RESEARCH PARTNERSHIPS
Group fr
PARTENARIATS DE RECHERCHE
Committee code
360
Committee name en
Collaborative Health Research Projects Selection Panel
Committee name fr
Comité de sélection de projets de recherche concertée sur la santé
Area of application code
9999
Area of application group en
Not available
Area of application group fr
Non disponible
Area of application en
Not available
Area of application fr
Non disponible
Research subject code
6400
Research subject group en
Life sciences research related to human health and disease
Research subject group fr
Sciences de la vie liées à la santé publique et aux maladies humaines
Research subject en
Life sciences research related to human health and disease
Research subject fr
Sciences de la vie liées à la santé publique et aux maladies humaines
Installment
inst:2 - 3
Partie
2
Nb partie
3
Application title
Development of a Blood Test for Colorectal Cancer based on Metabolomic Signature
Keyword
NSERC
Application summary
Colorectal cancer (CRC) is the second leading cause of cancer death in the western world.Ideally, CRC will be detected early because treatments become progressively morecomplicated, toxic and expensive in later disease stages, and the survival is best in earlystage of disease. That is the basis of screening. Currently, the gold standard screening test iscolonoscopy, which is invasive, expensive and difficult to perform on large populations. Onestrategy is to enrich the subgroup that requires a colonoscopy by doing a stool test (called afecal immunohistochemical test, FIT). The problem is that compliance for stool tests is lessthan 40% because testing stool is objectionable and inconvenient. We have developed ablood test based on the chemical composition of serum. This test is quite sensitive and it hasalready been tested on over 600 patients. In this project, in collaboration with Med-LifeDiscoveries and Innovate Calgary, as well as a multidisciplinary science team, we will furtherrefine the test, then create a diagnostic test that can be used in a typical clinical laboratory.Software will be developed to enhance the capability to analyze test results. Finally, we willtest the new diagnostic test on blood samples collected from close to 3500 individuals whohad screening colonoscopies. At the end, we will have a convenient, clinically applicable testthat will be tested in the future in a larger clinical trial that would inform regulatory agenciesand clinicians on the value of this new test as an alternative screening tool.